Predictive capacity of immune‐related adverse events and cytokine profiling in neoadjuvant immune checkpoint inhibitor trials for head and neck squamous cell carcinoma

Documenti analoghi

• Recurrent Inflammatory Myofibroblastic Tumor of Larynx Harboring a Novel THBS1::ALK Fusion
  di: Namra Ajmal, et al.
  Pubblicazione: (2024)
• Establishment of an animal model of immune‐related adverse events induced by immune checkpoint inhibitors
  di: Yuan Meng, et al.
  Pubblicazione: (2024)
• Improved survival with elevated BMI following immune checkpoint inhibition across various solid tumor cancer types
  di: Eric V. Mastrolonardo, et al.
  Pubblicazione: (2025)
• Tissue‐resident memory T cells in immunotherapy and immune‐related adverse events by immune checkpoint inhibitor
  di: Hao Xiong, et al.
  Pubblicazione: (2024)
• Blood and tissue correlates of steroid non-response in checkpoint inhibition-induced immune-related adverse events
  di: van Eijs, Mick, et al.
  Pubblicazione: (2025)